Denis Segota

Denis Segota

Baker & McKenzie LLP
Not admitted to practice law in this jurisdiction


Denis Segota is a partner in the Corporate & Securities Practice Group and a member of the Life Sciences Industry Group at Baker McKenzie in New York. Denis has over 20 years of experience in counselling clients in the life science industry. His clients range from early stage start-ups, life science venture and other private equity funds to multinational pharmaceutical companies. Denis assists companies with complex joint ventures, strategic alliances, licensing, and other partnering arrangements promoting the research, development, and commercialization of new products.

Practice Focus

He devotes much of his time to companies in the life sciences industry, including both the pharmaceutical and biotechnology sectors. In addition, Denis represents private equity firms investing in the food industry, as well as emerging growth technology companies. In addition to partnering and strategic alliances, Denis also handles mergers and acquisitions (M&A), including marketed product acquisitions and divestitures and private financing transactions, including representing private equity firms and companies in royalty monetization transactions.

Representative Legal Matters

  • Represented argenx in its strategic collaboration for Efgartigimod in Greater China, including USD 75 million in upfront Zai Lab equity and USD 100 million in near-term milestone and other payments.
  • Advised Bayer in its acquisition of gene therapy company Asklepios BioPharmaceutical, Inc. for USD 2 billion upfront and potential success-based milestone payments of up to an additional USD 2 billion.

  • Represented Takeda in the sale to Neuraxpharm of global rights to the prescription brand Buccolam® (indicated for the emergency treatment of epileptic children with prolonged acute convulsive seizures).

  • Advised Astellas in its acquisition of Xyphos Biosciences, a development-stage biotechnology company focused on immuno-oncology therapeutics, for a total transaction value of up to USD 665 million including USD 120 million upfront and potential future development milestone payments.

  • Represented H. Lundbeck A/S in its acquisition of Abide Therapeutics, a clinical-stage biopharmaceutical company focusing on multiple indications in neurology and psychiatry, for USD 250 million upfront and up to an additional USD 150 million in development and sales milestones.

Prior to joining the Firm, Denis provided counsel to:

  • AbbVie in a collaboration and option agreement with Mission Therapeutics to research and develop specified DUB inhibitors for the treatment of Alzheimer's Disease and Parkinson's Disease. 

  • AbbVie in its strategic collaboration with Alector to develop and commercialize medicines and treat Alzheimer's disease and other neurodegenerative disorders.

  • Astellas in its global commercialization agreement with Seattle Genetics Inc. to commercialize enfortumab vedotin.

  • Celgene in its global immuno-oncology collaboration with BeiGene to advance PD-1 inhibitor programs for solid tumor cancers.

  • Minerva in its licensing agreement with Janssen Pharmaceuticals for rights to Orexin 2 compounds for the EU, Switzerland, Liechtenstein, Iceland and Norway.

  • AbbVie in its collaboration agreement with Principia BioPharma for the development of oral immunoproteasome inhibitors.

  • HealthCare Royalty Partners (HCRP) in a royalty monetization transaction pursuant to which HCRP acquired certain royalty interests relating to medical; products containing botuliniumtoxin for the treatment of migraine headaches.

Professional Honors

  • Dealmakers Award to Baker McKenzie Life Sciences Group, NJLJ Professional Excellence 2020
  • Life Sciences Star, Financial & Corporate – Venture Capital, LMG Life Sciences, 2019
  • Band 4, Corporate/M&A, New Jersey, Chambers USA, 2020-2021
  • Ranked, Corporate/M&A, New Jersey, Chambers USA, 2018
  • Ranked, Chambers USA: America's Leading Lawyers for Business, 2011 - 2017
  • Ranked, The Legal 500, Mergers and Acquisitions, 2014

Professional Associations and Memberships

  • New Jersey Bar Association - Member


  • New Jersey~United States
  • Pennsylvania~United States


  • Rutgers University School of Law, New Jersey (JD) (1992)
  • Rutgers University (BS, cum laude) (1989)


  • English